

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 28, 2009

**BECTON, DICKINSON AND COMPANY**

---

(Exact Name of Registrant as Specified in Its Charter)

**New Jersey**

---

(State or Other Jurisdiction of Incorporation)

**001-4802**

**22-0760120**

---

(Commission File Number)

(IRS Employer Identification No.)

**1 Becton Drive, Franklin Lakes, New Jersey**

**07417-1880**

---

(Address of Principal Executive Offices)

(Zip Code)

**(201) 847-6800**

---

(Registrant's Telephone Number, Including Area Code)

**N/A**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On April 28, 2009, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2009. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- Revenues. We present international and total company revenue growth rates (including revenues relating to our safety-engineered devices) at constant foreign exchange rates. We believe that this allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
  - Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, for the quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our agreement to settle certain antitrust class action suits. This charge caused reported selling and administrative expense to be higher for these periods than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of selling and administrative expense are more indicative of BD's performance, and allow investors to more easily compare BD's selling and administrative expense for these periods to other periods.
  - Operating Income. We present BD's operating income, both alone and as a percentage of revenues, for the quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our agreement to settle certain antitrust class action suits. This charge caused reported operating income for these periods to be lower than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD's performance, and allow investors to more easily compare BD's operating income for these periods to other periods.
  - Income Taxes and Effective Tax Rate. We present BD's income taxes and effective tax rate for the quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our agreement to settle certain antitrust class action suits. This charge caused both our income taxes and our effective tax rate for these periods to be lower than they otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income taxes and effective tax rate are more indicative of BD's results, and allow investors to more easily compare BD's income taxes and effective tax rate for these periods to other periods.
-

- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for the quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our agreement to settle certain antitrust class action suits. This charge caused reported income from continuing operations for these periods to be lower than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's performance, and allow investors to more easily compare BD's operating income from continuing operations for these periods to other periods.
- Earnings Per Share. We present BD's diluted earnings per share for the quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our agreement to settle certain antitrust class action suits. This charge caused reported diluted earnings per share for these periods to be lower than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of diluted earnings per share are more indicative of BD's performance, and allow investors to more easily compare BD's diluted earnings per share for these periods to other periods.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

#### ITEM 8.01 OTHER EVENTS

On April 27, 2009, BD entered into a settlement agreement with the direct purchaser plaintiffs (which includes BD's distributors) in the following antitrust class actions: *Louisiana Wholesale Drug Company, Inc., et. al. vs. Becton Dickinson and Company* (Civil Action No. 05-1602, U.S. District Court, Newark, New Jersey), filed on March 25, 2005; *SAJ Distributors, Inc. et. al. vs. Becton Dickinson & Co.* (Case 2:05-CV-04763-JD, U.S. District Court, Eastern District of Pennsylvania), filed on

---

September 6, 2005; *Dik Drug Company, et. al. vs. Becton, Dickinson and Company* (Case No. 2:05-CV-04465, U.S. District Court, Newark, New Jersey), filed on September 12, 2005; *American Sales Company, Inc. et. al. vs. Becton, Dickinson & Co.* (Case No. 2:05-CV-05212-CRM, U.S. District Court, Eastern District of Pennsylvania), filed on October 3, 2005; and *Park Surgical Co. Inc. et. al. vs. Becton, Dickinson and Company* (Case 2:05-CV-05678- CMR, U.S. District Court, Eastern District of Pennsylvania), filed on October 26, 2005. These actions have been consolidated under the caption "*In re Hypodermic Products Antitrust Litigation*", as has been reported in the past, most recently in the Company's Form 10-K for 2008. Under the terms of the settlement agreement, which is subject to preliminary and final approval by the court following notice to potential class members, the Company will pay \$45 million into a settlement fund in exchange for a release by all potential class members of the direct purchaser claims related to the products and acts enumerated in the Complaint, as well as a dismissal of the case with prejudice. The release would not cover potential class members which affirmatively opt out of the settlement. No settlement has been reached to date with the indirect purchaser plaintiffs in these cases, which will continue to the extent these cases relate to their claims.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated April 28, 2009, which is furnished pursuant to Item 2.02.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated April 28, 2009, which is furnished pursuant to Item 2.02.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Paranicas  
Dean J. Paranicas  
Vice President, Corporate  
Secretary and Public Policy

Date: April 28, 2009

---

# News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453  
Colleen T. White, Corporate Communications – 201-847-5369

## **BD ANNOUNCES RESULTS FOR SECOND FISCAL QUARTER**

- Reports earnings per share from continuing operations of \$1.06, or \$1.18 after excluding specified item
- Reaffirms guidance for full fiscal year 2009 earnings per share from continuing operations, excluding specified item

**Franklin Lakes, NJ (April 28, 2009)** – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of \$1.741 billion for the second fiscal quarter ended March 31, 2009, representing a decrease of 0.4 percent from the prior year period. This quarter's revenue growth rate reflects the unfavorable impact from foreign currency translation, which overall is estimated to account for 3.4 percentage points.

"In the face of global economic pressures, we are pleased to have achieved top-line growth in all three segments after adjusting for the negative impact of foreign currency translation. This growth, along with our continued focus on disciplined expense and currency risk management, has enabled us to deliver adjusted earnings in line with our expectations," stated Edward J. Ludwig, Chairman and Chief Executive Officer. "Our strong performance for the first half of fiscal 2009, combined with our commitment to continue to drive efficiency throughout BD, gives us the confidence to reaffirm our guidance for full-year adjusted earnings."

---

## **Second Quarter and Six-Month Period of Fiscal Year 2009 and 2008 Earnings**

Reported diluted earnings per share from continuing operations for the second quarter were \$1.06. Second quarter results included a pre-tax charge of \$45 million (11 cents diluted earnings per share from continuing operations) relating to the settlement agreement with the direct purchaser plaintiffs (which includes BD's distributors) in the antitrust class actions, as described in BD's Current Report on Form 8-K filed with the SEC today. Second quarter fiscal 2009 diluted earnings per share from continuing operations, excluding the charge of 11 cents, of \$1.18 increased by 8 percent over diluted earnings per share from continuing operations of \$1.09 for the prior year period. For the six-month period ending March 31, 2009, reported diluted earnings per share from continuing operations were \$2.32. Excluding the aforementioned charge of 11 cents, diluted earnings per share from continuing operations for the six-month period in fiscal 2009 were \$2.43, representing an increase of 12.5 percent over diluted earnings per share from continuing operations of \$2.16 from the prior year period.

### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$897 million, representing a decrease of 3 percent from the prior year period after taking into account an estimated 5 percentage points of unfavorable impact from foreign currency translation. On a currency neutral basis, the increase in worldwide sales of Medical Surgical Systems products was offset in part by the expected decline in sales of prefillable devices in the U.S. For the six-month period ended March 31, 2009, the BD Medical segment reported a 2 percent decrease in revenue growth after taking into account an estimated 4 percentage points of unfavorable impact from foreign currency translation. On a currency neutral basis, BD Medical revenues for the six-month period increased by 2 percent.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$540 million, representing an increase of 2 percent from the prior year period after taking into account an estimated 3 percentage

---



points of unfavorable impact from foreign currency translation. Increased sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems were partially offset by a decline in the sales of flu testing products due to a mild flu season in the U.S. For the six-month period ended March 31, 2009, the BD Diagnostics segment reported 3 percent revenue growth after taking into account an estimated 3 percentage points of unfavorable impact from foreign currency translation. On a currency neutral basis, BD Diagnostics revenues for the six-month period increased by 6 percent.

In the BD Biosciences segment, worldwide revenues for the quarter were \$304 million, representing an increase of 3 percent from the prior year period. Strong international sales growth of research instruments and reagents, primarily in Western Europe and Japan, were offset in part by a slowdown in research-related capital spending in the U.S., particularly in the academic and biotech markets. For the six-month period ended March 31, 2009, the BD Biosciences segment reported 7 percent revenue growth after taking into account an estimated 1 percentage point favorable impact from foreign currency translation. On a currency neutral basis, BD Biosciences revenues for the six-month period increased by 6 percent.

### **Geographic Results**

Second quarter revenues in the U.S. were \$778 million, representing a decrease of 1 percent from the prior year period. Revenues outside the U.S. were \$963 million, representing flat revenues from the prior year period, and reflect an estimated 6 percentage points of unfavorable impact from foreign currency translation.

For the six-month period ended March 31, 2009, revenues in the U.S. were \$1.587 billion, representing an increase of 1 percent from the prior year period. Revenues outside of the U.S. were \$1.887 billion, representing an increase of 0.5 percent from the prior year period, and reflect an estimated 6 percentage points of unfavorable impact from foreign currency translation.

---

## **Fiscal 2009 Outlook for Full Year**

Excluding the specified item, the Company reaffirms that diluted earnings per share from continuing operations for the full fiscal year 2009 will increase approximately 9 to 11 percent over diluted earnings per share from continuing operations of \$4.46 for the fiscal year 2008. The Company expects that reported diluted earnings per share from continuing operations for the full fiscal year 2009 will increase 7 to 9 percent.

## **Conference Call Information**

A conference call regarding BD's second fiscal quarter results and its expectations for the full fiscal year will be broadcast live on BD's website, [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 10:00 a.m. (ET) Tuesday, April 28, 2009. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 800-642-1687 (domestic) and 706-645-9291 (international), Conference ID: 92219921, through the close of business on Tuesday, May 5, 2009.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

## **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release, including the section entitled "Fiscal 2009 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; competitive factors; pricing*

---

*and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

---

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended March 31,		
	2009	2008	% Change
REVENUES	\$ 1,740,804	\$ 1,746,925	(0.4)
Cost of products sold	838,101	853,807	(1.8)
Selling and administrative	440,502	415,523	6.0
Research and development	98,734	96,034	2.8
TOTAL OPERATING COSTS AND EXPENSES	1,377,337	1,365,364	0.9
OPERATING INCOME	363,467	381,561	(4.7)
Interest income	4,312	8,005	(46.1)
Interest expense	(7,495)	(8,098)	(7.4)
Other (expense) income, net	(5,701)	828	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	354,583	382,296	(7.2)
Income tax provision	93,256	106,661	(12.6)
INCOME FROM CONTINUING OPERATIONS	261,327	275,635	(5.2)
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(32) AND \$347, RESPECTIVELY	(53)	550	NM
NET INCOME	\$ 261,274	\$ 276,185	(5.4)
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.09	\$ 1.13	(3.5)
(Loss) income from discontinued operations	\$ -	\$ -	-
Net income	\$ 1.09	\$ 1.13	(3.5)
Diluted:			
Income from continuing operations	\$ 1.06	\$ 1.09	(2.8)
(Loss) income from discontinued operations	\$ -	\$ -	-
Net income	\$ 1.06	\$ 1.09	(2.8)
AVERAGE SHARES OUTSTANDING			
Basic	240,239	244,869	
Diluted	245,890	252,788	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
(Unaudited; Amounts in thousands, except per share data)

	Three Months Ended March 31, 2009		
	As Reported	Litigation Charge (1)	Excluding Item
Selling and administrative as a % of revenues	\$ 440,502 25.3%	\$ (45,000)	\$ 395,502 22.7%
Operating Income as a % of revenues	363,467 20.9%	45,000	408,467 23.5%
Income taxes effective tax rate	93,256 26.3%	17,100	110,356 27.6%
Income from continuing operations as a % of revenues	261,327 15.0%	27,900	289,227 16.6%
<u>Diluted earnings per share</u>			
Income from continuing operations (2)	\$ 1.06	\$ 0.11	\$ 1.18

- (1) Represents the charge relating to the settlement agreement with the direct purchaser plaintiffs (which includes BD's distributors) in the antitrust class actions.
- (2) Total per share amounts may not add due to rounding.
-

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	Six Months Ended March 31,		
	2009	2008	% Change
REVENUES	\$ 3,474,309	\$ 3,452,692	0.6
Cost of products sold	1,642,399	1,683,654	(2.5)
Selling and administrative	850,444	837,240	1.6
Research and development	196,191	187,561	4.6
TOTAL OPERATING COSTS AND EXPENSES	2,689,034	2,708,455	(0.7)
OPERATING INCOME	785,275	744,237	5.5
Interest income	5,962	21,534	(72.3)
Interest expense	(15,319)	(18,438)	(16.9)
Other income, net	3,711	1,535	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	779,629	748,868	4.1
Income tax provision	206,233	202,337	1.9
INCOME FROM CONTINUING OPERATIONS	573,396	546,531	4.9
(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(23) AND \$734, RESPECTIVELY	(40)	1,201	NM
NET INCOME	\$ 573,356	\$ 547,732	4.7
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.38	\$ 2.23	6.7
(Loss) income from discontinued operations	\$ -	\$ -	-
Net income (1)	\$ 2.38	\$ 2.24	6.3
Diluted:			
Income from continuing operations	\$ 2.32	\$ 2.16	7.4
(Loss) income from discontinued operations	\$ -	\$ -	-
Net income	\$ 2.32	\$ 2.16	7.4
AVERAGE SHARES OUTSTANDING			
Basic	241,330	244,580	
Diluted	247,436	253,288	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL INFORMATION  
(Unaudited; Amounts in thousands, except per share data)

	Six Months Ended March 31, 2009		
	As Reported	Litigation Charge (1)	Excluding Item
Selling and administrative as a % of revenues	\$ 850,444 24.5%	\$ (45,000)	\$ 805,444 23.2%
Operating Income as a % of revenues	785,275 22.6%	45,000	830,275 23.9%
Income taxes effective tax rate	206,233 26.5%	17,100	223,333 27.1%
Income from continuing operations as a % of revenues	573,396 16.5%	27,900	601,296 17.3%
<u>Diluted earnings per share</u>			
Income from continuing operations	\$ 2.32	\$ 0.11	\$ 2.43

(1) Represents the charge relating to the settlement agreement with the direct purchaser plaintiffs (which includes BD's distributors) in the antitrust class actions.

---

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
 (Unaudited; Amounts in thousands)

	Three Months Ended March 31,		
	2009	2008	% Change
<b><u>BD MEDICAL</u></b>			
United States	\$ 388,966	\$ 388,281	0.2
International	508,358	533,971	(4.8)
<b>TOTAL</b>	<b>\$ 897,324</b>	<b>\$ 922,252</b>	<b>(2.7)</b>
<b><u>BD DIAGNOSTICS</u></b>			
United States	\$ 285,113	\$ 281,088	1.4
International	254,527	249,484	2.0
<b>TOTAL</b>	<b>\$ 539,640</b>	<b>\$ 530,572</b>	<b>1.7</b>
<b><u>BD BIOSCIENCES</u></b>			
United States	\$ 104,039	\$ 114,581	(9.2)
International	199,801	179,520	11.3
<b>TOTAL</b>	<b>\$ 303,840</b>	<b>\$ 294,101</b>	<b>3.3</b>
<b><u>TOTAL REVENUES</u></b>			
United States	\$ 778,118	\$ 783,950	(0.7)
International	962,686	962,975	-
<b>TOTAL</b>	<b>\$ 1,740,804</b>	<b>\$ 1,746,925</b>	<b>(0.4)</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	Six Months Ended March 31,		
	2009	2008	% Change
<b>BD MEDICAL</b>			
United States	\$ 796,474	\$ 795,772	0.1
International	991,626	1,035,764	(4.3)
<b>TOTAL</b>	<b>\$ 1,788,100</b>	<b>\$ 1,831,536</b>	<b>(2.4)</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 572,681	\$ 560,576	2.2
International	507,150	492,747	2.9
<b>TOTAL</b>	<b>\$ 1,079,831</b>	<b>\$ 1,053,323</b>	<b>2.5</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 217,790	\$ 217,653	0.1
International	388,588	350,180	11.0
<b>TOTAL</b>	<b>\$ 606,378</b>	<b>\$ 567,833</b>	<b>6.8</b>
<b>TOTAL REVENUES</b>			
United States	\$ 1,586,945	\$ 1,574,001	0.8
International	1,887,364	1,878,691	0.5
<b>TOTAL</b>	<b>\$ 3,474,309</b>	<b>\$ 3,452,692</b>	<b>0.6</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		
	2009	2008	% Change
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 242,350	\$ 232,447	4.3
Diabetes Care	97,196	96,883	0.3
Pharmaceutical Systems	43,065	52,779	(18.4)
Ophthalmic Systems	6,355	6,172	3.0
<b>TOTAL</b>	<b>\$ 388,966</b>	<b>\$ 388,281</b>	<b>0.2</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 147,436	\$ 140,674	4.8
Diagnostic Systems	137,677	140,414	(1.9)
<b>TOTAL</b>	<b>\$ 285,113</b>	<b>\$ 281,088</b>	<b>1.4</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 71,770	\$ 78,269	(8.3)
Discovery Labware	32,269	36,312	(11.1)
<b>TOTAL</b>	<b>\$ 104,039</b>	<b>\$ 114,581</b>	<b>(9.2)</b>
<b>TOTAL UNITED STATES</b>	<b>\$ 778,118</b>	<b>\$ 783,950</b>	<b>(0.7)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2009	2008	International		
			Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 230,233	\$ 248,269	(7.3)	3.7	(11.0)
Diabetes Care	87,033	90,577	(3.9)	2.7	(6.6)
Pharmaceutical Systems	178,085	181,660	(2.0)	3.2	(5.2)
Ophthalmic Systems	13,007	13,465	(3.4)	3.8	(7.2)
<b>TOTAL</b>	<b>\$ 508,358</b>	<b>\$ 533,971</b>	<b>(4.8)</b>	<b>3.4</b>	<b>(8.2)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 131,029	\$ 133,518	(1.9)	7.0	(8.9)
Diagnostic Systems	123,498	115,966	6.5	11.5	(5.0)
<b>TOTAL</b>	<b>\$ 254,527</b>	<b>\$ 249,484</b>	<b>2.0</b>	<b>9.1</b>	<b>(7.1)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 159,223	\$ 141,452	12.6	11.5	1.1
Discovery Labware	40,578	38,068	6.6	4.7	1.9
<b>TOTAL</b>	<b>\$ 199,801</b>	<b>\$ 179,520</b>	<b>11.3</b>	<b>10.1</b>	<b>1.2</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$ 962,686</b>	<b>\$ 962,975</b>	<b>-</b>	<b>6.1</b>	<b>(6.1)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2009	2008	Total		
			Reported	FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 472,583	\$ 480,716	(1.7)	4.0	(5.7)
Diabetes Care	184,229	187,460	(1.7)	1.5	(3.2)
Pharmaceutical Systems	221,150	234,439	(5.7)	(1.6)	(4.1)
Ophthalmic Systems	19,362	19,637	(1.4)	3.6	(5.0)
<b>TOTAL</b>	<b>\$ 897,324</b>	<b>\$ 922,252</b>	<b>(2.7)</b>	<b>2.0</b>	<b>(4.7)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 278,465	\$ 274,192	1.6	5.9	(4.3)
Diagnostic Systems	261,175	256,380	1.9	4.1	(2.2)
<b>TOTAL</b>	<b>\$ 539,640</b>	<b>\$ 530,572</b>	<b>1.7</b>	<b>5.0</b>	<b>(3.3)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 230,993	\$ 219,721	5.1	4.5	0.6
Discovery Labware	72,847	74,380	(2.1)	(3.1)	1.0
<b>TOTAL</b>	<b>\$ 303,840</b>	<b>\$ 294,101</b>	<b>3.3</b>	<b>2.6</b>	<b>0.7</b>
<b>TOTAL REVENUES</b>	<b>\$1,740,804</b>	<b>\$1,746,925</b>	<b>(0.4)</b>	<b>3.0</b>	<b>(3.4)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		
	2009	2008	% Change
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 498,605	\$ 485,192	2.8
Diabetes Care	199,008	195,409	1.8
Pharmaceutical Systems	85,717	102,757	(16.6)
Ophthalmic Systems	13,144	12,414	5.9
<b>TOTAL</b>	<b>\$ 796,474</b>	<b>\$ 795,772</b>	<b>0.1</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 296,666	\$ 283,974	4.5
Diagnostic Systems	276,015	276,602	(0.2)
<b>TOTAL</b>	<b>\$ 572,681</b>	<b>\$ 560,576</b>	<b>2.2</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 149,150	\$ 145,629	2.4
Discovery Labware	68,640	72,024	(4.7)
<b>TOTAL</b>	<b>\$ 217,790</b>	<b>\$ 217,653</b>	<b>0.1</b>
<b>TOTAL UNITED STATES</b>	<b>\$ 1,586,945</b>	<b>\$ 1,574,001</b>	<b>0.8</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2009	2008	International		
			Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 454,480	\$ 494,336	(8.1)	1.9	(10.0)
Diabetes Care	180,813	181,438	(0.3)	6.0	(6.3)
Pharmaceutical Systems	330,214	333,623	(1.0)	3.7	(4.7)
Ophthalmic Systems	26,119	26,367	(0.9)	5.8	(6.7)
<b>TOTAL</b>	<b>\$ 991,626</b>	<b>\$1,035,764</b>	<b>(4.3)</b>	<b>3.3</b>	<b>(7.6)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 259,953	\$ 261,687	(0.7)	7.7	(8.4)
Diagnostic Systems	247,197	231,060	7.0	11.7	(4.7)
<b>TOTAL</b>	<b>\$ 507,150</b>	<b>\$ 492,747</b>	<b>2.9</b>	<b>9.6</b>	<b>(6.7)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 311,364	\$ 279,205	11.5	10.7	0.8
Discovery Labware	77,224	70,975	8.8	6.4	2.4
<b>TOTAL</b>	<b>\$ 388,588</b>	<b>\$ 350,180</b>	<b>11.0</b>	<b>9.8</b>	<b>1.2</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,887,364</b>	<b>\$1,878,691</b>	<b>0.5</b>	<b>6.2</b>	<b>(5.7)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2009	2008	Total		
			Reported	FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 953,085	\$ 979,528	(2.7)	2.3	(5.0)
Diabetes Care	379,821	376,847	0.8	3.8	(3.0)
Pharmaceutical Systems	415,931	436,380	(4.7)	(1.1)	(3.6)
Ophthalmic Systems	39,263	38,781	1.2	5.8	(4.6)
<b>TOTAL</b>	<b>\$1,788,100</b>	<b>\$1,831,536</b>	<b>(2.4)</b>	<b>1.9</b>	<b>(4.3)</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 556,619	\$ 545,661	2.0	6.0	(4.0)
Diagnostic Systems	523,212	507,662	3.1	5.2	(2.1)
<b>TOTAL</b>	<b>\$1,079,831</b>	<b>\$1,053,323</b>	<b>2.5</b>	<b>5.6</b>	<b>(3.1)</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 460,514	\$ 424,834	8.4	7.9	0.5
Discovery Labware	145,864	142,999	2.0	0.8	1.2
<b>TOTAL</b>	<b>\$ 606,378</b>	<b>\$ 567,833</b>	<b>6.8</b>	<b>6.1</b>	<b>0.7</b>
<b>TOTAL REVENUES</b>	<b>\$3,474,309</b>	<b>\$3,452,692</b>	<b>0.6</b>	<b>3.7</b>	<b>(3.1)</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,				
	2009	2008	% Change		
			Reported	FX Neutral	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 255,026	\$ 247,316	3.1	3.1	-
International	136,718	126,418	8.1	18.9	(10.8)
<b>TOTAL</b>	<b>\$ 391,744</b>	<b>\$ 373,734</b>	<b>4.8</b>	<b>8.5</b>	<b>(3.7)</b>

	Six Months Ended March 31,				
	2009	2008	% Change		
			Reported	FX Neutral	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$ 523,995	\$ 513,567	2.0	2.0	-
International	270,798	247,303	9.5	19.1	(9.6)
<b>TOTAL</b>	<b>\$ 794,793</b>	<b>\$ 760,870</b>	<b>4.5</b>	<b>7.6</b>	<b>(3.1)</b>